Roche HPV Test Cleared by FDA | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche announced today the clearance of its cobas HPV test by the US Food and Drug Administration.

The test, the company said, identifies women who are at greatest risk for developing cervical cancer, and is the only cervical cancer screening test approved by the FDA that allows HPV 16 and 18 genotyping concurrently with high-risk HPV testing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.